Medicine’s next frontier: Detect, decode, decipher

[madman]

Experts Ashish Tripathi, Founder CEO of Tzar Labs and Epigenres, Dr Ravi Jasuja, Indegene Chair for Digital Health, Plasksha University, and Dr Ambarish Satwik, Vascular surgeon, Sir Ganga Ram Hospital & writer discuss the giant leaps medicine is taking into uncharted territory.

The field of molecular diagnostics is galloping ahead and involves the taking of DNA or RNA, the unique genetic code found in our cells, and examining and analysing the data from specific sequences that can flag the potential occurrence of a disease. For instance, in the fight against cancer, early detection is the Holy Grail and the most accepted early detection test for cancer is the HrC Test, a quick, minimally invasive method to evaluate expression levels of rare stem cell markers. In this session, experts in diagnostics focus on the future of the ingenuity that is transforming molecular pathology.

 

[madman]

About | TZAR LABS

Tzar Labs is pioneering a journey to detect all cancers, earlier than existing technologies with a novel blood test. We bring science and technology together on a mission to evolve the quality of human lives and healthcare.

Tzar Labs is a molecular diagnostic company that specializes in the detection and prognosis of cancer at its earliest stage. A first of its kind blood test that can detect cancer even years before the symptoms occur is paving the way for efficient early detection and treatment. Here the staging and presence or absence of cancer are determined by screening for a set of genetic markers in precursor stem cell populations in blood.

Tzar Labs has pioneered a medical breakthrough in molecular diagnostics that can help the identification of cancer along with common diseases such as diabetes, cardiovascular diseases, Alzheimer’s, to name a few. According to research, 72% of rare diseases are genetic. Our proprietary technology is developed to aid the early detection of these conditions.

Tzar Labs has co-developed the technology with an Indian firm Epigeneres Biotech Pvt Ltd., Epigeneres has a licensing agreement with Tzar for the territory of India. The companies also have some shared resources as part of the agreements between the companies.

About Diagnostic Technology | TZAR LABS

*Tzar has a proprietary technology of isolating progenitor stem cells from the blood and using genetic expression of these cells and algorithms to detect HrC and distinguish between cancer absent, cancer imminent and cancer present and also distinguish between different stages of cancer. It also uses exome and transcriptome analysis to provide primary organ, primary disease, pathways impacted and secondary tumour analysis. The data is not only useful in terms of early detection but also helps oncologists decide appropriate treatment protocols, analyse treatment efficacy and improve response time and efficiency. This technology will save lives by improving detection and analysis with a simple blood test.

Clinical Trials | TZAR LABS